Keynote address by Myriam Chalabi at ESMOGI24
Toni Choueiri shared on X:
“Keynote address at ESMOGI24 with superstar Myriam Chalabi– Immunotherapy for MSS-CRC: The last frontier.”
Source: Toni Choueiri/X
Toni Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School.
He is the Medical Director of International Strategic Initiatives at Dana-Farber and past President of the Medical Staff at DFCI (2016-2018).
Dr. Choueiri is an elected member of the American Society of Clinical Investigation (ASCI). In addition, he is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania.
Dr. Myriam Chalabi, a medical oncologist and researcher based at the Netherlands Cancer Institute, specializes in gastrointestinal tract cancer. Her research primarily focuses on immunotherapy for gastrointestinal cancers.
In 2017, she initiated a clinical investigation called the NICHE trial, aiming to explore the potential benefits of immunotherapy for early-stage colon cancer patients.
Through this trial, Dr. Chalabi identified a subtype of colon cancer patients deficient in mismatch repair, exhibiting DNA replication errors, who demonstrate remarkable responsiveness to immunotherapy. She possesses expertise in neoadjuvant immunotherapies for these specific indications.
Additionally, Dr. Chalabi underscores the significance of biomarkers in patient selection for immuno-oncology clinical trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023